Title |
Phototherapy 660 nm for the prevention of radiodermatitis in breast cancer patients receiving radiation therapy: study protocol for a randomized controlled trial
|
---|---|
Published in |
Trials, August 2014
|
DOI | 10.1186/1745-6215-15-330 |
Pubmed ID | |
Authors |
Marina Moreira Costa, Sidney Benedito Silva, Ana Luiza Pereira Quinto, Priscilla Furtado Souza Pasquinelli, Vanessa de Queiroz dos Santos, Gabriela de Cássia Santos, Daniela Francescato Veiga |
Abstract |
Breast neoplasms are the second most common type of cancer worldwide, and radiation therapy is a key component of their treatment. Acute skin reactions are one of the most common side effects of radiation therapy, and prevention of this adverse event has been investigated in several studies. However, a clinically applicable, preventative treatment remains unavailable. It has been demonstrated that application of a low-power laser can promote tissue repair. Therefore, the aim of this trial is to evaluate the effectiveness of an indium gallium aluminum phosphorus (InGaAIP) laser operated at 660 nm in preventing radiodermatitis in women undergoing adjuvant radiotherapy for breast cancer. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Scientists | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | <1% |
Unknown | 118 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 23 | 19% |
Student > Bachelor | 20 | 17% |
Researcher | 8 | 7% |
Student > Postgraduate | 6 | 5% |
Unspecified | 6 | 5% |
Other | 18 | 15% |
Unknown | 38 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 33 | 28% |
Nursing and Health Professions | 10 | 8% |
Unspecified | 6 | 5% |
Physics and Astronomy | 4 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
Other | 18 | 15% |
Unknown | 44 | 37% |